Clinical Trials · NCT06760546

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

Phase
Phase 3
Recruitment status
Recruiting
Sponsor
Rhythm Pharmaceuticals, Inc.
Enrollment
39
Start date
Sep 2025
Locations
11 sites, United States, United Kingdom
Primary endpoint
Mean % change in BMI
View Setmelanotide compound reference